Gold prices steady ahead of Fed decision; weekly weakness noted
SAN DIEGO - Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), a $3.71 billion market cap pharmaceutical company with excellent financial health according to InvestingPro analysis, has announced the appointment of Allyson McMillan-Youngblood as the new Senior Vice President of its Rare Disease Franchise. McMillan-Youngblood will join the commercial leadership team, focusing on the growth of DAYBUE® and preparing the company for upcoming product launches. The appointment comes as Acadia demonstrates strong commercial execution, with revenue growing over 22% in the last twelve months.
With over two decades of experience in the pharmaceutical industry, McMillan-Youngblood has held various sales and commercial roles at Pfizer and Bristol Myers Squibb (BMS). Her most recent position at BMS as Senior Vice President and Business Unit Head, U.S. Oncology, involved strategic leadership for acquisitions in rare tumors, leading to successful product launches and market share increases.
Catherine Owen Adams, CEO of Acadia, expressed enthusiasm for McMillan-Youngblood’s track record and expertise in commercialization and rare disease markets. Acadia anticipates that her leadership will be crucial in expanding the DAYBUE brand and further developing the company’s pipeline of therapies for rare diseases.
McMillan-Youngblood’s appointment comes as Acadia continues its commitment to neuroscience and rare disease treatment. The company is known for its FDA-approved drugs for Parkinson’s disease psychosis and Rett syndrome and is currently working on treatments for Prader-Willi syndrome and Alzheimer’s disease psychosis, among others. With a strong balance sheet showing more cash than debt and a healthy current ratio of 2.88, Acadia appears well-positioned to fund its development pipeline. For deeper insights into Acadia’s financial health and growth prospects, investors can access comprehensive analysis through InvestingPro’s detailed research reports, which cover over 1,400 US stocks.
Allyson McMillan-Youngblood, a Florida A&M University graduate, has been recognized for her leadership skills and dedication to patient care throughout her career. She expressed her eagerness to contribute to Acadia’s mission and to help drive the growth of DAYBUE as well as the launch of new therapies for patients with rare diseases.
This strategic hire underlines Acadia’s ongoing efforts to strengthen its position in the neuroscience and rare disease sectors. The company’s stock has shown strong momentum, with a 34.93% return over the past six months, though InvestingPro data suggests the stock is currently trading in overbought territory. The information is based on a press release statement and market data.
In other recent news, Acadia Pharmaceuticals has reported significant developments that could impact its financial outlook. Deutsche Bank upgraded Acadia’s stock from Hold to Buy, raising the price target to $35 due to a favorable patent litigation outcome for its drug Nuplazid, which now has patent protection until 2038. This legal victory against generic manufacturers is expected to enhance Nuplazid’s revenue projections beyond 2030. Additionally, Acadia has signed a new 12-year lease for office space in Princeton, New Jersey, aligning its operations for future growth.
RBC Capital Markets maintains an Outperform rating on Acadia with a $26 price target, citing optimism from accelerated timelines for the Phase III ACP-101 program in Prader-Willi Syndrome. BMO Capital Markets also raised its price target for Acadia to $28, emphasizing the importance of the extended IP protection for Nuplazid, which they believe could stabilize future revenue streams. Morgan Stanley increased its price target to $24, reflecting the extended market exclusivity for Nuplazid due to the recent court ruling.
Acadia’s upcoming Research and Development Day in June 2025 is anticipated to provide further insights into its pipeline and strategy. The company is also preparing for updates on the Phase 3 trials for Prader-Willi syndrome in late 2025. These developments underscore Acadia’s strategic positioning and potential for sustained growth in the pharmaceutical market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.